← Back to Search

Tubal Occlusion Device

FemBloc® Permanent Contraceptive System for Birth Control (BLOC Trial)

N/A
Waitlist Available
Research Sponsored by Femasys Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the safety of a new permanent birth control method called FemBloc. It is designed for women who want to permanently prevent pregnancy. The procedure works by blocking the fallopian tubes, stopping eggs from reaching the uterus. The study will follow participants for several years to ensure long-term safety.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of subjects who experience an Adverse Event divided by the number of subjects exposed to the FemBloc treatment procedure
Other study objectives
Number of subjects who experience an Adverse Event divided by the number of subjects exposed to the FemBloc Biopolymer
Number of subjects who experience an Adverse Event divided by the number of subjects exposed to the FemBloc Confirmation test

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: FemBloc® Permanent Contraceptive SystemExperimental Treatment1 Intervention
Treatment of women who desire permanent birth control (female sterilization) by occlusion of the fallopian tubes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FemBloc® Permanent Contraceptive System
2017
N/A
~50

Find a Location

Who is running the clinical trial?

Femasys Inc.Lead Sponsor
5 Previous Clinical Trials
1,172 Total Patients Enrolled
Study DirectorStudy DirectorSponsor Clinical Affairs
1,278 Previous Clinical Trials
499,605 Total Patients Enrolled
~6 spots leftby Dec 2025